Quick Answer
Aprea Therapeutics, Inc. reported Total Assets of $15.93 million for the year ending 2025.
- Aprea Therapeutics, Inc. showed a decrease of -33.6% in Total Assets from 2024 to 2025.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $57.34 million | Q1 2020: $125.13 million | Q2 2020: $114.82 million | Q3 2020: $102.83 million | Q1 2021: $80.39 million | Q2 2021: $71.55 million | Q3 2021: $62.48 million | Q1 2022: $50.34 million | Q2 2022: $40.68 million | Q3 2022: $33.62 million | Q1 2023: $32.02 million | Q2 2023: $28.68 million | Q3 2023: $25.77 million | Q1 2024: $33.20 million | Q2 2024: $29.96 million | Q3 2024: $26.89 million | Q1 2025: $20.22 million | Q2 2025: $17.31 million | Q3 2025: $14.32 million.
- Over the full 8 years of available data (2018 to 2025), Aprea Therapeutics, Inc.'s Total Assets has declined by 75.9%.
- Historical annual values: Fiscal year 2025: $15.93 million | Fiscal year 2024: $23.98 million | Fiscal year 2023: $22.65 million | Fiscal year 2022: $30.16 million | Fiscal year 2021: $56.82 million | Fiscal year 2020: $92.81 million | Fiscal year 2019: $133.61 million | Fiscal year 2018: $66.02 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: